Evaluation of the Safety of Sanyak (Dioscoreae Rhizoma) Pharmacopuncture According to the Extraction Method: A Double-blind Randomized Controlled Trial  by Ko, Min-kyung & Hong, Kwon-eui
Available online at www.sciencedirect.com
Journal of Acupuncture and Meridian Studies
journa l homepage: www. jams-kp i .com
J Acupunct Meridian Stud 2013;6(1):41e51- RESEARCH ART ICLE -Evaluation of the Safety of Sanyak
(Dioscoreae Rhizoma) Pharmacopuncture
According to the Extraction Method:
A Double-blind Randomized Controlled TrialMin-kyung Ko, Kwon-eui Hong*Department of Oriental Medicine, Daejeon University, Daejeon, Republic of Korea
Available online 31 December 2012Received: Nov 10, 2011
Revised: Sep 18, 2012
Accepted: Sep 19, 2012
KEYWORDS
acupuncture;
double-blind*
Co
pI
htrandomized
controlled trial;
pharmacopuncture;
safety;
Sanyak (Dioscoreae
rhizoma)Corresponding author. 22-5, Daejeon
E-mail: hkeacu@dju.kr.
pyright ª 2013, International Pharm
SSN 2005-2901 eISSN 2093-8152
tp://dx.doi.org/10.1016/j.jams.201Abstract
The study was conducted to evaluate the safety of Sanyak (Dioscoreae rhizoma) pharma-
copuncture by injecting to healthy participants. Among the subjective symptoms, pain
after the injection was statistically significant in the group injected with alcohol extract
of Sanyak. The mean platelet volume and blood in the urinalysis after the injections were
statistically significant between groups. After injections, the total protein level in liver
function tests and hematocrit changed significantly. However, all of these changes were
within normal limits, and Sanyak pharmacopuncture did not cause any severe physical
responses or subjective symptoms and may, therefore, be considered safe.1. Introduction
Pharmacopuncture is an effective therapy in Oriental
medicine. A solution extracted from medicinal herbs is
injected into acupuncture points according to the condition
of the patient [1,2]. Pharmacopuncture with different
types of herbs is effective at treating disease [3].Oriental Hospital, Dae-heung-Dong
acopuncture Institute
2.12.003Sanyak (Dioscoreae rhizoma) is one of the most
frequently used herbs in Oriental medicine, and studies
have demonstrated that it has a protective effect against
DNA damage, antioxidant activity [4], a hypoglycemic
effect [5], and is preventive against diabetic neuropathy
[6]. In a recent study, pharmacopuncture using Sanyak
extract stimulated growth-promoting activity in an injured, Jung-Gu, Daejeon, Republic of Korea.
42 M.-k. Ko, K.-e. Hongperipheral nerve [7]. This regenerating effect of Sanyak
pharmacopuncture can be used to treat many nervous
system diseases such as cerebrovascular accident and Bell’s
palsy; however, the safety and potential adverse effects of
Sanyak pharmacopuncture have rarely been investigated.
Therefore, this study was conducted to evaluate the
safety of Sanyak pharmacopuncture by evaluating physical
responses, subjective symptoms [8], liver function tests,
complete blood cell counts, and urinalysis results before
and after injection in patients. Our study demonstrated
that Sanyak pharmacopuncture is safe.
2. Materials and methods
2.1. Experimental participants
A total of 25 participants (12 men) were enrolled in this
trial from September 15, 2010 to October 10, 2010.
2.2. Experimental materials
2.2.1. Pharmacopuncture extract preparation
2.2.1.1. Alcohol extraction
A total of 250 g of Sanyak was washed in water for injection
and boiled in 2 L of water at 105C for 120 minutes. After
increasing the heat to 107C, the lower layer of fluid was
collected in a 2-L Pyrex container through a distiller cooling
tube and a funnel. The extract was collected for approxi-
mately 4 hours. After extraction, the fluid was stored at
a temperature below 4C for 1 day to separate inorganic
substances. After this process, the fluid was filtered
through a 1 mm Nutsche Filter in an aseptic room at the
Korea Pharmacopuncture Institute. Sanyak fluid was
agitated with alcohol for 24 hours three times and filtered
through the 1 mm Nutsche Filter. The concentrated solution
was mixed with water for injection and freeze-dried.
A total of 4 g of Sanyak powder was added to forty 20 mL
Sanyak injections, which contained 0.05 g of powder and
were controlled at pH 7.3 with a salinity of 0.9%. The
Sanyak injections were agitated with 99.99% N2 and filtered
with 0.2-mm paper. The product was divided into 20 mL and
sterilized at 121C with 1.5 atmospheres for 30 minutes.
Before use, quality control (microorganisms, endotoxins,
and purity) was performed and the Sanyak injection was
stored at a temperature below 4C.
2.2.1.2. Normal saline extraction
250 g of Sanyak was washed in water for the injection and
boiled in 2 L of water at 105C for 120 minutes. After
increasing the heat to 107C, the lower layer of fluid was
collected in a 2-L Pyrex container through a distiller cooling
tube and a funnel. The extract was collected for approxi-
mately 4 hours. After extraction, the fluid was stored at
a temperature below 4C for 1 day to separate inorganic
substances. A total of 1390 g of Sanyak was extracted and
controlled at pH 7.2e7.3 with a salinity of 0.9%. After
agitation, the filtering, dividing, N2 agitation, high pressure
sterilization, quality control, and storage procedures were
the same as those for the alcohol extraction.2.3. Experimental methods
2.3.1. Participants agreement
The participants who were enrolled in this trial understood
its purpose, the methods, the randomized probability, the
potential adverse reactions, the confidentiality guarantee,
the reward, and the right to leave the trial. After receiving
a written consent form from each participant, the trial was
initiated.
2.3.2. Inclusion and exclusion criteria
2.3.2.1. Inclusion criteria
Patients were enrolled in the trial according to the
following inclusion criteria: age between 19 years and 65
years; and demographic characteristics, past medical
history, physical examination results (blood pressure,
pulse, body temperature, and respiration rate), x-ray
results, electrocardiogram results and pathological inves-
tigation results that were within normal limits.
2.3.2.2. Exclusion criteria
Participants who met the following criteria were excluded:
(1) injection phobia; (2) acute or chronic infection; (3)
administered steroid drugs within 4 weeks before the trial;
(4) acute severe cardiovascular disease; (5) past history of
a skin ailment, which could affect the trial; (6) participa-
tion in another clinical trial within 3 months before the first
injection; (7) renal disease, acute or chronic renal failure,
or nephritic syndrome; (8) liver function problems [prob-
lems with aspartate aminotransferase (AST), alanine
aminotransferase (ALT), or g-glutamyltranspeptidase
(g-GTP); (9) diabetes; (10) took antipsychotic medication
within 2 months before the trial; (11) were inconsistently
available for the trial because of physical examinations or
other reasons; (12) pregnant or breast feeding women or
fertile women who did not use contraception; (13) partic-
ipants who considered to be inconsistently available for the
trial by investigator.
2.3.2.3. Randomized sampling
Participants were selected according to the demographic
characteristics, past medical history, physical examination
results (blood pressure, pulse, body temperature and
respiration rate), x-ray results, electrocardiogram results
and pathological investigation results. A total of 25
participants were divided into the following three groups by
a medical statistics expert according to block randomiza-
tion: 10 participants for the distilled saline Sanyak
group (DDG), 10 participants for the alcohol extracted
Sanyak group (ADG), and five participants for the control
(normal saline) group (NSG).
2.3.2.4. Blinding method
Because sharing the treatment information with the
participants could alter the outcome of the trial, the
participants were unaware of the treatments they received
until the trial was finished. To maintain a blinded trial, the
researcher determined the suitability of the participants,
received written consent, numbered the participants,
managed the schedules, treated and consulted the partic-
ipants and created the Case report Form (CRFs) of the
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but was unaware of the treatments that each participant
took received. The pharmacopuncture was manufactured
by a third person according to the randomized sampling list.
Therefore, the physician who administered the pharmaco-
puncture injections to the participants did not know the
type of treatment that was given.
The prepared randomized method was unknown by the
investigators, and the randomized sampling results were
available to the investigators when requested by telephone
or e-mail. The randomized sampling results were main-
tained separately.2.3.2.5. Pharmacopuncture treatment method
The pharmacopuncture treatment was injected three
times/week, for a total of 10 times by a physician who was
an expert in Oriental medicine. The DDG was injected with
the normal saline extraction pharmacopuncture, the ADG
was injected with the alcohol extraction pharmaco-
puncture and the NSG was injected with normal saline at
10 acupuncture points, 0.1 mL at each point for a total of
1 mL per treatment. The 10 points, which are frequently
used in acupuncture, were selected at both sides of the
face (ST6), upper limb (LI11), lower limb (ST36), body
(GB29, ST25). The depth of the injections were 5 mm for
ST6, 5e10 mm for LI11, and 10 mm for ST36, GB29 and
ST25, according to Pharmacopuncturology of the Korea
Pharmacopuncture Institute [2]2.3.2.6. Measurements
The main validity measurement variables were evaluated by
comparing the results of the liver function tests, complete
blood cell counts, and urinalysis before and after the
injections. The participants fasted for at least 14 hours and
underwent a liver function test, a complete blood cell count,
and urinalysis before receiving the injection and after
completing 10 rounds of pharmacopuncture. The liver
function test assessed the levels of total protein, albumin, T-
bilirubin, AST, ALT, alkaline phosphatase (ALP), g-GTP,
lactate dehydrogenase (LDH), cholesterol, triglyceride,
high-density lipoprotein (HDL)-cholesterol, low-density
lipoprotein (LDL)-cholesterol, glucose (fasting blood sugar;
FBS), creatinine, blood urea nitrogen (BUN) and albumin/
globulin (A/G) ratio. The complete blood cell count included
white blood cells (WBC), red blood cells (RBC), hemoglobin,
hematocrit, erythrocyte sedimentation rate (ESR), plate-
lets, mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin concen-
tration (MCHC), red blood cell distribution width, platelet
distribution width (PDW), plateletcrit (PCT), mean platelet
volume (MPV), segmented cells, monocytes, and lympho-
cytes. The urinalysis included color, specific gravity, pH,
albumin, leukocytes, nitrite, glucose, urobilinogen, ketone,
bilirubin, blood, RBC, WBC, and epithelial cells.
The secondary validity measurement variables were the
physical responses and the subjective symptoms, which
were evaluated and recorded at every injection. Blood
pressure, pulse, and body temperaturewere assessed before
the injection. Physical responses, such as skin flares, an
itching sensation, a burning sensation, edema, subcutaneous
bleeding, an abscess at the injection site, discoloration, andinduration were evaluated 5 minutes after the injection.
Additionally, the subjective symptoms, including pain upon
injection, pain after the injection, pain 5 minutes after the
injection, pain 24 hours after the injection, nausea, dizzi-
ness, cold sweat, chest discomfort, hyperventilation,
palpitation, numbness, headache, and insomnia were
assessed. After 10 rounds of the injection, the safety of the
pharmacopuncture was evaluated according to themain and
secondary validity measurements.
2.4. Statistical analysis
The validity measurement was based on an intention-to-
treat (ITT) analysis result and on a preprotocol analysis. The
evaluation of the safety is mainly used in the ITT analysis.
To compare the demographic characteristics and the
basic data of each group, the KruskaleWallis test was used
for the continuous variables and Pearson’s Chi-square test
or Fisher’s exact test was used for the categorical vari-
ables. If there was a statistically significant variable,
a generalized linear mixed model was used. A p-value
<0.05 was considered statistically significant.
3. Results
3.1. Participant demographics
There were no differences between the three groups
according to the demographic characteristics (Table 1).
3.2. Comparison of physical responses and
subjective symptoms between groups
3.2.1. Comparison of physical responses between groups
After all of the total injections, no significant differences
were observed between the groups according to the
presence of skin flares, an itching sensation, a burning
sensation, edema, subcutaneous bleeding, an abscess at
injection site, or induration (p > 0.05). Discoloration was
statistically significant, and occurred in 1.0%, 0.0%, and
16.0% of the DDG, ADG, and NSG, respectively (pZ 0.0000;
Table 2).
3.2.2. Comparison of the subjective symptoms between
the groups
The presence of pain upon injection, pain 5 minutes after the
injection, pain 24 hours after the injection, nausea, dizziness,
cold sweat, chest discomfort, hyperventilation, palpitation,
numbness, headache, and insomnia was not significantly
different among the groups (p > 0.05). However, pain after
the injection was statistically significant and occurred in
28.0%, 46.0%, and 38.8% of the patients in the DDG, ADG, and
NSG groups, respectively (pZ 0.0306; Table 3).
3.2.3. Generalized linear mixed model analysis of
physical responses and subjective symptoms, which were
below 0.2 in the group comparison
The presence of skin flares, edema, discoloration, indura-
tion, pain upon injection, pain after the injection, and
headaches was not statistically significant (p > 0.05).
Table 1 Clinical characteristics of the distillation Sanyak (DDG), alcohol Sanyak (ADG), and normal saline groups (NDG).
DDG ADG NDG p
Fisher’s exact test KruskaleWallis test
Total number 10 10 5 d d
Gender Male (%) 4 (40.00) 6 (60.00) 2 (40.00) 0.6744 d
Female (%) 6 (60.00) 4 (40.00) 3 (60.00)
Smoking Yes (%) 3 (30.00) 2 (20.00) 1 (20.00) 1.0000 d
No (%) 7 (70.00) 8 (80.00) 4 (80.00)
Drinking Yes (%) 4 (40.00) 4 (40.00) 2 (40.00) 1.0000 d
No (%) 6 (60.00) 6 (60.00) 3 (60.00)
Age (y) 35.50  6.86a 35.50  9.45 37.60  9.47 d 0.7796
Height (cm) 166.80  8.71 169.80  9.68 167.20  6.41 d 0.7530
Weight (kg) 65.00  11.72 66.10  9.31 63.4  12.93 d 0.7912
Blood pressure
(mmHg)
Systolic 123.30  12.91 125.60  12.29 114.20  19.42 d 0.4046
Diastolic 75.60  7.07 73.30  8.83 64.60  13.81 d 0.2465
Pulse (/min) 80.20  5.69 78.40  5.01 73.00  9.21 d 0.3571
Temperature (C) 36.30  0.29 36.29  0.19 36.16  0.20 d 0.4853
Respiration (/min) 20.40  0.84 21.00  0.66 20.00  1.22 d 0.0921
a ZMean  standard deviation.
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symptoms between groups at each visit
The presence of pain upon injection on the sixth visit was
statistically significant (p Z 0.0495).
3.3. Safety evaluation
3.3.1. Comparison of pathological investigation results
between the groups before the injection
3.3.1.1. Liver function test
No significant differences were observed in the total protein,
albumin, A/G ratio, T-bilirubin, AST, ALT, g-GTP, LDH,Table 2 Physical responses after injections in the distillation S
(NDG).
DDG ADG
Skin flare Y (%) 6 (6.00) 8 (8.00)
N (%) 94 (94.00) 92 (92.00)
Itching sensation Y (%) 2 (2.00) 1 (1.00)
N (%) 98 (98.00) 99 (99.00)
Burning sensation Y (%) 3 (3.00) 5 (5.00)
N (%) 97 (97.00) 95 (95.00)
Edema Y (%) 1 (1.00) 6 (6.00)
N (%) 99 (99.00) 94 (94.00)
Subcutaneous bleeding Y (%) 6 (6.00) 6 (6.00)
N (%) 94 (94.00) 94 (94.00)
Abscess at the infection site Y (%) 0 (0.00) 0 (0.00)
N (%) 100 (100.00) 99a (100.00)
Discoloration Y (%) 1 (1.00) 0 (0.00)
N (%) 99 (99.00) 99a (100.00)
Induration Y (%) 6 (6.00) 10 (10.00)
Y Z yes; N Z no.
*p < 0.05.
a Z1 missing value.cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol,
FBS, creatinine, and BUN. However, the ALP level was
statistically significant (pZ 0.0362; Table 4)3.3.1.2. Complete blood cell count
The complete blood cell counts were not statistically
significant different between groups (p > 0.05; Table 5)3.3.1.3. Urinalysis
The urinalysis results were not statistically significant
different between groups (p > 0.05; Table 6)anyak (DDG), alcohol Sanyak (ADG), and normal saline groups
NDG p
Fisher’s
exact test
Pearson’s
chi-square test
Generalized linear
mixed model
0 (0.00) d 0.1296 0.2122
50 (100.00)
0 (0.00) 0.3057 d d
50 (100.00)
0 (0.00) 0.3283 d d
50 (100.00)
0 (0.00) 0.0967 d 0.5770
50 (100.00)
4 (8.00) d 0.5838 d
46 (92.00)
0 (0.00) d d d
50 (100.00)
8 (16.00) 0.0000* d 0.2231
42 (84.00)
0 (0.00) d 0.0605 0.2865
Table 3 Subjective symptoms after injections in the distillation Sanyak (DDG), alcohol Sanyak (ADG), and normal saline groups
(NDG).
DDG ADG NDG p
Fisher’s
exact test
Pearson’s
chi-square test
Generalized linear
mixed model
Pain upon injection Y (%) 54 (54.00) 66 (66.00) 28 (28.00) d 0.1973 0.3867
N (%) 46 (46.00) 34 (34.00) 22 (22.00)
Pain after the injection Y (%) 28 (28.00) 46 (46.00) 19a (38.78) d 0.0306* 0.5220
N (%) 72 (72.00) 54 (54.00) 30 (61.22)
Pain 5 min after the injection Y (%) 11 (11.00) 17 (17.00) 10 (10.00) d 0.2846 d
N (%) 89 (89.00) 83 (3.00) 40 (40.00)
Pain 24 h after the injection Y (%) 0 (0.00) 1 (1.00) 0 (0.000) 1.0000 d d
N (%) 100 (100.00) 99 (99.00) 50 (100)
Nausea Y (%) 0 (0.00) 0 (0.00) 0 (0.00) d d d
N (%) 100 (100.00) 100 (100.00) 50 (100)
Dizziness Y (%) 2 (2.00) 0 (0.00) 1 (2.00) 0.4209 d d
N (%) 98 (98.00) 100 (100.00) 49 (98.00)
Cold sweat Y (%) 0 (0.00) 2 (2.00) 0 (0.00) 0.3574 d d
N (%) 100 (100.00) 98 (98.00) 50 (100)
Chest discomfort Y (%) 0 (0.00) 1 (1.00) 0 (0.00) 1.000 d d
N (%) 100 (100.00) 99 (99.00) 50 (100)
Hyperventilation Y (%) 0 (0.00) 0 (0.00) 0 (0.00) d d d
N (%) 100 (100.00) 100 (100.00) 50 (100.00)
Palpitation Y (%) 0 (0.00) 1 (1.00) 0 (0.00) 1.000 d d
N (%) 100 (100.00) 99 (99.00) 50 (100.00)
Numbness Y (%) 0 (0.00) 0 (0.00) 0 (0.00) d d d
N (%) 100 (100.00) 100 (100.00) 100 (100.00)
Headache insomnia Y (%) 4 (4.00) 0 (0.00) 0 (0.00) 0.0755 d 0.3679
N (%) 96 (96.00) 100 (100.00) 50 (100.00)
Y Z yes; N Z no.
*p < 0.05.
a Z1 missing value.
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results between groups after the injections
3.3.2.1. Liver function test
The liver function test results were not significantly
different between groups (p > 0.05; Table 7).
3.3.2.2. Complete blood cell count
No significant differences were observed in the WBC, RBC,
hemoglobin level, hematocrit, ESR, platelet count, MCV,
MCH, MCHC, RDW, PDW, PCT, segmented cell count,
monocyte, and lymphocyte count among the groups
(p > 0.05). However, there were statistically significant
differences in MPV, (p Z 0.0382; Table 8).
3.3.2.3. Urinalysis
The color, specific gravity, pH, albumin levels, leukocyte
count, presence of nitrite, glucose levels, urobilinogen
levels, presence of ketones, bilirubin levels, RBC, WBC, and
epithelial cell count were not statistically significant
(p > 0.05). However, the presence of blood was statistically
significant (p Z 0.0399; Table 9).
3.3.3. Comparison of pathological investigation results
between groups before and after injections
3.3.3.1. Liver function test
In the liver function tests that were performed before
and after the injections, differences in levels ofalbumin, A/G ratio, T-bilirubin, AST, ALT, ALP, g-GTP,
LDH, cholesterol, triglyceride, HDL-cholesterol, LDL-
cholesterol, FBS, creatinine, and BUN were not statisti-
cally significant when compared between the groups
(p > 0.05). However, the total protein levels in the ADG
were increased in the liver function tests that were
performed after the injections compared with those
performed before the injections. In contrast, the total
protein levels were decreased in the DDG and NSG in the
liver function tests that were performed after the
injections compared with those before the injections.
Therefore, there was statistical significance in the
protein levels in these three groups after the injection
(p Z 0.0451; Table 10).
3.3.3.2. Complete blood cell count
Differences in WBC, RBC, hemoglobin level, ESR, platelet
count, MCV, MCH, MCHC, RDW, PDW, PCT, MPV, segmented
cell count, monocyte count, and lymphocyte count were
not statistically significant (p > 0.05). Hematocrit increased
after the injections in the ADG but decreased in DDG and
NSG (p Z 0.0272; Table 11).3.3.3.3. Urinalysis
The urinalysis results before and after the injections were
not statistically significant (p > 0.05).
Table 4 Mean  standard deviation differences in liver function test results between distillation Sanyak (DDG), alcohol Sanyak
(ADG), and normal saline groups (NDG) before the injections.
DDG ADG NDG p
KruskaleWallis test
Total protein (rr 65e80 g/L) 75.6  3.5 76.3  3.5 78.0  1.4 0.3846
Albumin (rr 35e53 g/L) 45.7  2.3 46.5  2.5 46.4  2.7 0.7804
A/G ratio (rr 1.1e2.5) 1.56  0.19 1.59  0.19 1.52  0.27 0.9048
T-bilirubin (rr 2.0e12 mg/L) 7.8  2.5 6.8  2.1 8.2  3.5 0.7475
AST (rr 0e40 IU/L) 22.10  6.57 22.70  4.78 19.40  5.27 0.5676
ALT (rr 0e35 IU/L) 18.70  10.47 23.50  7.53 14.80  6.22 0.0598
ALP (rr 96e254 IU/L) 57.30  9.44 66.00  16.88 49.20  9.57 0.0362*
g-GTP (rr 0e73 IU/L) 21.80  15.20 25.40  18.18 15.20  9.03 0.2321
Cholesterol (rr 1.25e2.50 g/L) 1.876  0.408 1.954  0.414 1.726  0.167 0.5375
Triglyceride (rr 0.42e1.68 g/l) 1.321  0.900 2.050  2.239 1.122  0.519 0.6379
HDL-C (rr 300e650 mg/L) 517.3  75.7 477.4  49.4 476.2  71.2 0.2454
LDL-C (rr 0e1.4 g/L) 1.226  0.372 128.80  35.28 115.82  20.37 0.9018
FBS (rr 0.70e1.10 g/L) 0.888  0.124 0.909  0.066 0.880  0.069 0.8477
Creatinine (rr 6.0e12 mg/L) 8.5  1.1 9.4  2.2 11.0  2.4 0.6544
BUN (rr 80e200 mg/L) 141.7  26.3 161.8  51.5 144.8  22.9 0.7846
Mean  standard deviation.
*p < 0.05.
A/G Z albumin/globulin; ALP Z alkaline phospatase; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
BUN Z blood urea nitrogen; FBS Z fasting blood sugar; g-GTP Z g-glutamyltranspeptidase; HDL-C Z high-density lipoprotein-
cholesterol; LDL-C Z low-density lipoprotein-cholesterol; rr Z reference range.
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There were no significant differences between the three
groups according to age, gender, smoking, drinking history,
height, and weight (Table 1).
Considering the physical responses as secondary validity
measurement variables, discoloration was statisticallyTable 5 Mean  standard deviation differences in complete blo
(ADG), and normal saline groups (NDG) before injections.
DDG A
WBC (rr 45e110  109/L) 56.40  14.42 5
RBC (rr 45e65  109/L) 464.00  44.68 47
Hemoglobin (rr 13e17 g/L) 141.7  18.3 1
Hematocrit (rr 38e52%) 42.07  4.61 4
ESR (rr 0e10 mm) 15.00  13.41 1
Platelets (rr 15e450  1012/L) 24.58  5.64 2
MCV (rr 80e94 fL) 90.60  3.22 8
MCH (rr 26e32 pg) 30.46  1.52 2
MCHC (rr 330e370 g/L) 336.1  7.6 3
RDW (rr 10.9e15.7%) 13.04  1.02 1
PDW (rr 15.5e18.5%) 17.24  0.42 1
PCT (rr 0.1e1%) 0.18  0.04
MPV (rr 6.3e10 fL) 7.70  0.71
Segmented cells (rr 40e80 %) 58.09  7.88 5
Monocytes (rr 2e10%) 3.46  1.11
Lymphocytes (rr 15e45%) 38.40  7.73 4
ESR Z erythrocyte sedimentation rate; MCH Z mean corpuscular he
MCV Z mean corpuscular volume; MPV Z mean platelet volume; PC
blood cell; rr Z reference range; WBC Z white blood cells.significant in the NSG compared to the other groups, and
occurred in 16% (p Z 0.0000; Table 2). Significant discol-
oration occurred with repeated subcutaneous injections of
normal saline; however, the number of participants in the
NSG with discoloration was limited and this symptom was
not considered an adverse event. Therefore, additional
studies are needed.od counts between distillation Sanyak (DDG), alcohol Sanyak
DG NDG p
KruskaleWallis
test
8.70  10.71 60.20  12.23 0.8944
5.50  41.18 444.40  44.97 0.5202
41.0  24.9 136.2  19.4 0.7879
2.47  6.23 40.90  5.43 0.7435
1.10  8.15 14.80  7.25 0.7423
4.06  5.02 25.42  8084 0.9284
9.14  9.57 91.90  4066 0.8434
9.57  4.03 30.60  1.92 0.8942
30.2  14.6 332.6  5.0 0.4245
2.96  1.22 12.98  0.38 0.4455
6.67  0.45 17.26  0.82 0.0542
0.17  0.04 0.16  0.05 0.7165
6.77  0.98 6.72  0.83 0.0792
2.84  6.21 59.70  3.83 0.0940
4.25  0.81 3.54  0.47 0.1005
2.93  6.46 36.76  3.92 0.1847
moglobin; MCHC Z mean corpuscular hemoglobin concentration;
T Z plateletcrit; PDW Z platelet distribution width; RBC Z red
Table 6 Differences in urinalysis results between distillation Sanyak (DDG), alcohol Sanyak (ADG), and normal saline groups
(NDG) before injections.
DDG ADG NDG p
KruskaleWallis
test
Fisher’s
exact test
SG (rr 1.005e1.025) 1.02  0.00a 1.02  0.00 1.02  0.00 0.1258 d
pH (rr 5e8) 5.10  0.31 5.40  0.65 5.60  1.34 0.5175 d
Color  (%) 2 (20.00) 5 (50.00) 1 (20.00) d 0.3086
þ (%) 0 (0.00) 1 (10.00) 1 (20.00)
þþ (%) 8 (80.00) 4 (40.00) 3 (60.00)
Leukocyte  (%) 8 (80.00) 8 (80.00) 3 (60.00) d 0.3427
þ (%) 1 (10.00) 0 (0.00) 2 (40.00)
þþ (%) 1 (10.00) 2 (20.00) 0 (0.00)
Nitrite  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Albumin  (%) 10 (100.00) 10 (100.00) 4 (80.00) d 0.2000
TR (%) 0 (0.00) 0 (0.00) 1 (20.00)
Glucose  (%) 10 (100.00) 9 (90.00)b 5 (100.00) d d
Urobilinogen  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Ketone  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Bilirubin  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Blood  (%) 7 (70.00)b 8 (80.00) 4 (80.00) d 0.8679
þ (%) 0 (0.00) 1 (10.00) 1 (20.00)
þþ (%) 1 (10.00) 0 (0.00) 0 (0.00)
þþþ (%) 0 (0.00) 1 (10.00) 0 (0.00)
TR (%) 1 (10.00) 0 (0.00) 0 (0.00)
RBC (rr 0e1/HPF) 0e1 (%) 6 (60.00) 7 (70.00) 2 (40.00) d 0.6494
1e2 (%) 2 (20.00) 1 (10.00) 2 (40.00)
2e3 (%) 0 (0.00) 0 (0.00) 1 (20.00)
3e5 (%) 1 (10.00) 1 (10.00) 0 (0.00)
5e7 (%) 1 (10.00) 0 (0.00) 0 (0.00)
15e20 (%) 0 (0.00) 1 (10.00) 0 (0.00)
WBC (rr 0e3/HPF) 0e1 (%) 5 (50.00) 7 (70.00) 3 (60.00) d 0.6575
1e2 (%) 2 (20.00) 1 (10.00) 0 (0.00)
2e3 (%) 1 (10.00) 0 (0.00) 0 (0.00)
3e5 (%) 1 (10.00) 0 (0.00) 0 (0.00)
5e7 (%) 0 (0.00) 1 (10.00) 2 (40.00)
7e10 (%) 1 (10.00) 1 (10.00) 0 (0.00)
Epithelial cells (rr 0e5/LPF) 1e2 (%) 5 (50.00) 6 (60.00) 2 (40.00) d 0.8462
2e3 (%) 0 (0.00) 0 (0.00) 1 (20.00)
3e5 (%) 1 (10.00) 0 (0.00) 1 (20.00)
5e7 (%) 1 (10.00) 1 (10.00) 0 (0.00)
10e15 (%) 1 (10.00) 1 (10.00) 0 (0.00)
15e20 (%) 2 (20.00) 1 (10.00) 0 (0.00)
20e30 (%) 0 (0.00) 1 (10.00) 1 (20.00)
Bacteria  (%) 9 (90.00) 7 (70.00) 4 (80.00) d 0.8094
a few (%) 1 (10.00) 3 (30.00) 1 (20.00)
HPFZ high-powered field; LPFZ low-powered field; RBCZ red blood cell; rrZ reference range; SGZ specigic gravity; TRZ trace;
WBC Z white blood cells.
a ZMean  standard deviation.
b Z1 missing value.
The safety of Sanyak pharmacopuncture 47Among the subjective symptoms, differences in pain after
the injection was statistically significant and occurred in
28%, 46%, and 39% of the patients in the DDG, ADG, and NSG,
respectively (p Z 0.0306; Table 2). Alcohol extraction
pharmacopuncture has a lower filtration rate than normal
saline extraction and absorption of the herbal fluid occurred
late; therefore, the reaction to the pressure hyperalgesiaincreased the pain and the duration of the pain [9]. This
study demonstrated a high rate of pain after the injection in
only the ADG. To decrease the pain after the injection of
alcohol-extraction pharmacopuncture, additional studies
are needed. In the physical responses and the subjective
symptoms at each visit, pain upon injection on the sixth visit
was statistically significant (pZ 0.0495).
Table 7 Mean  standard deviation differences in the liver function test results distillation Sanyak (DDG), alcohol Sanyak
(ADG), and normal saline groups (NDG) after injections.
DDG ADG NDG p
KruskaleWallis test
Total protein (rr 65e80 g/L) 74.9  4.2 77.9  4.1 76.0  3.1 0.3235
Albumin (rr 35e53 g/L) 44.5  3.4 47.5  2.6 45.4  1.9 0.1522
A/G ratio (rr1.1e2.5) 1.49  0.15 1.58  0.20 1.52  1.80 0.6506
T-bilirubin (rr 2.0e12 mg/L) 8.6  3.0 8.9  3.2 8.2  2.2 0.9087
AST (rr 0e40 IU/L) 22.80  7.09 23.30  6.66 22.40  7.76 0.9294
ALT (rr 0e35 IU/L) 19.5  11.83 22.20  9.68 18.20  7.98 0.5708
ALP (rr 96e254 IU/L) 58.40  12.00 64.30  15.16 46.40  11.54 0.0913
g-GTP (rr 0e73 IU/L) 23.00  16.33 29.20  21.24 17.20  12.31 0.1914
Cholesterol (rr 1.25e2.50 g/L) 1.979  0.369 1.991  0.362 1.782  0.140 0.5114
Triglyceride (rr 0.42e1.68 g/L) 1.116  0.549 1.134  0.757 0.894  0.476 0.5596
HDL-C (rr 300e650 mg/L) 510.3  68.7 500.4  47.5 465.2  72.1 0.3249
LDL-C (rr 0e1.4 g/L) 1.299  .0336 1.378  .0313 1.217  0.203 0.6900
FBS (rr 0.70e1.10 g/L) 0.931  0.102 0.967  0.043 0.910  0.111 0.2125
Creatinine (rr 6.0e12 mg/L) 9.0  1.4 9.6  2.2 9.0  1.5 0.8907
BUN (80e200 mg/L) 123.0  19.6 152.6  43.0 127.0  32.0 0.1021
A/G Z albumin/globulin; ALP Z alkaline phospatase; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
BUN Z blood urea nitrogen; FBS Z fasting blood sugar; g-GTP Z g-glutamyltranspeptidase; HDL-C Z high-density lipoprotein-
cholesterol; LDL-C Z low-density lipoprotein-cholesterol; rr Z reference range.
48 M.-k. Ko, K.-e. HongThe difference in ALP level was statistically significant
among the three groups before the injections
(p Z 0.0362); however, there was no statistical signifi-
cance among the groups after the injections (p Z 0.0913;
Tables 4 and 7). The difference in the ALP levels between
the three groups was due to the predisposition of theTable 8 Mean  SD differences in complete blood counts be
normal saline groups (NDG) after injections.
DDG ADG
WBC (rr 45e110  109/L) 63.80  16.23 66.
RBC (rr 45e65  109/L) 454.20  56.15 424.
Hemoglobin (rr 13e17 g/L) 13.82  1.97 13.
Hematocrit (rr 38e52%) 41.09  5.51 42.
ESR (rr 0e10 mm) 13.80  13.23 11.
Platelets (rr 15e450  1012/L) 24.36  4.69 25.
MCV (rr 80e94 fL) 90.38  2.77 89.
MCH (rr 26e32 pg) 30.36  1.12 20.
MCHC (rr 330e370 g/L) 33.59  0.53 32.
RDW (rr 10.9e15.7%) 13.16  1.34 13.
PDW (rr 15.5e18.5%) 17.12  0.65 17.
PCT (rr 0.1e1%) 0.20  0.04 0.
MPV (rr 6.3e10 fL) 7.89  0.85 6.
Segmented cells (rr 40e80 %) 59.73  10.59 58.
Monocytes (rr 2e10%) 2.67  1.08 3.
Lymphocytes (rr 15e45%) 37.60  1.75 38.
*p < 0.05.
ESR Z erythrocyte sedimentation rate; MCH Z mean corpuscular he
MCV Z mean corpuscular volume; MPV Z mean platelet volume; PC
blood cell; rr Z reference range; WBC Z white blood cells.participants, and did not affect the safety of the Sanyak
pharmacopuncture.
Significant changes were observed in the complete blood
cell counts after the injections (p > 0.05). After the
injections, the difference in MPV level was statistically
significant (p Z 0.0382; Tables 5 and 8). The MPV istween distillation Sanyak (DDG), alcohol Sanyak (ADG), and
NDG p
KruskaleWallis test
10  21.47 58.00  10.79 0.6214
06  152.49 415.20  53.45 0.2486
80  2.31 12.98  2.04 0.6295
60  5.98 38.24  5.69 0.3515
40  7.54 14.00  4.35 0.8890
08  4.23 23.20  8.53 0.7343
83  9.59 92.00  4.76 0.4152
74  3.95 32.20  1.72 0.5178
98  1.25 34.07  0.89 0.1802
04  1.33 12.58  0.27 0.8759
15  0.82 16.70  0.60 0.5319
18  0.06 0.14  0.05 0.1496
87  0.93 6.86  0.86 0.0382*
42  8.54 57.94  3.72 0.9017
34  1.32 3.52  0.70 0.1199
24  8.44 38.54  3.95 0.9299
moglobin; MCHC Z mean corpuscular hemoglobin concentration;
T Z plateletcrit; PDW Z platelet distribution width; RBC Z red
Table 9 Differences in urinalysis results between distillation Sanyak (DDG), alcohol Sanyak (ADG), and normal saline groups
(NDG) after injections.
DDG ADG NDG p
KruskaleWallis
test
Fisher’s exact
test
SG 1.02  0.00a 1.02  0.00 1.01  0.00 0.2910 d
pH 5.30  0.67 5.80  0.58 5.80  0.83 0.1465 d
Color  (%) 1 (10.00) 1 (10.00) 1 (20.00) d 0.5027
þ (%) 2 (20.00) 3 (30.00) 3 (60.00)
þþ (%) 5 (50.00) 6 (60.00) 1 (20.00)
þþþ (%) 2 (20.00) 0 (0.00) 0 (0.00)
Leukocyte  (%) 8 (80.00) 8 (80.00) 3 (60.00) d 0.3427
þ (%) 1 (10.00) 0 (0.00) 2 (40.00)
þþ (%) 1 (10.00) 2 (20.00) 0 (0.00)
Nitrite  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Albumin  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Glucose  (%) 10 (100.00) 10 (100.00) 5 (100.00) d d
Urobilinogen  (%) 10 (100.00) 9 (90.00)b 5 (100.00) d d
Ketone  (%) 8 (80.00) 10 (100.00) 4 (80.00) d 0.3913
TR (%) 2 (20.00) 0 (0.00) 1 (20.00)
Bilirubin  (%) 10 (100.00) 10 (100.00) 5 (100.00) d -
Blood  (%) 10 (100.00) 8 (10.00) 3 (60.00) d 0.0399*
þ (%) 0 (0.00) 1 (10.00) 0 (0.00)
þþþ (%) 0 (0.00) 1 (10.00) 0 (0.00)
TR (%) 0 (0.00) 0 (0.00) 2 (40.00)
RBC (rr 0e1/HPF) 0e1 (%) 9 (90.00) 8 (80.00) 4 (80.00) d 0.7984
1e2 (%) 1 (10.00) 0 (0.00) 1 (20.00)
3e5 (%) 0 (0.00) 1 (10.00) 0 (0.00)
20e30 (%) 0 (0.00) 1 (10.00) 0 (0.00)
WBC (rr 0e3/HPF) 0e1 (%) 9 (90.00) 8 (80.00) 3 (60.00) d 0.3532
1e2 (%) 1 (10.00) 0 (0.00) 1 (20.00)
2e3 (%) 0 (0.00) 1 (10.00) 0 (0.00)
7e10 (%) 0 (0.00) 0 (0.00) 1 (20.00)
10e15 (%) 0 (0.00) 1 (10.00) 0 (0.00)
Epithelial cells (rr 0e5/LPF) 1e2 (%) 7 (70.00) 6 (60.00) 2 (40.00) d 0.0745
2e3 (%) 0 (0.00) 1 (10.00) 1 (20.00)
5e7 (%) 0 (0.00) 0 (0.00) 1 (20.00)
7e10 (%) 3 (30.00) 0 (0.00) 0 (0.00)
10e15 (%) 0 (0.00) 2 (20.00) 0 (0.00)
20e30 (%) 0 (0.00) 1 (10.00) 1 (20.00)
Bacteria  (%) 10 (100.00) 8 (80.00) 3 (60.00) d 0.1206
a few (%) 0 (0.00) 2 (20.00) 2 (40.00)
*p < 0.05.
HPF Z high-powered field; LPF Z low-powered field; RBC Z red blood cell; rr Z reference range; SG Z specific gravity; TR Z trace;
WBC Z white blood cells.
a ZMean  standard deviation.
b Z1 missing value.
The safety of Sanyak pharmacopuncture 49a measure of the average platelet volume in the platelet
distribution. Because the MPV before and after the injec-
tions was within the normal range, this variable did not
affect the safety of Sanyak pharmacopuncture.
After the injections, the presence of blood in the urinal-
ysis was statistically significant (pZ 0.0399; Tables 6 and 9).
In the ADG and the DDG, the number of participants who had
blood detected in urine decreased after the injections; the
number of participants in the who had blood detected in
urine increased after the injections. This result suggestedthat Sanyak pharmacopuncture has a positive effect on blood
in urine; however, additional studies are needed.
In the comparison of the liver function test results
between the groups before and after the injections, the
difference in total protein level was statistically significant
(p Z 0.0451; Table 10). The total protein level was
increased in the ADG after the injection but decreased in
the DDG and NSG and remained within a normal limit after
injections. Therefore, those alterations did not affect the
safety of Sanyak pharmacopuncture.
Table 11 Comparison of the complete blood cell counts between distillation Sanyak (DDG), alcohol Sanyak (ADG), and normal
saline groups (NDG) before and after the injections.
DDG ADG NDG p
KruskaleWallis test
WBC (rr 45e110  109/L) 7.40  9.52 7.40  19.22 2.25  9.62 0.1978
RBC (rr 45e65  109/L) 9.80  18.94 51.43  157.04 29.2  28.52 0.1567
Hemoglobin (rr 13e17 g/L) 0.35  0.72 0.30  1.17 0.64  0.92 0.3730
Hematocrit (rr 38e52%) 0.98  1.98 0.13  1.10 2.66  2.60 0.0272*
ESR (rr 0e10 mm) 1.20  2.25 0.30  3.09 0.80  4.71 0.3810
Platelets (rr 15e450  1012/L) 0.22  3.19 1.02  2.49 2.22  1.13 0.0705
MCV (rr 80e94 fL) 0.22  0.93 0.69  0.98 0.10  0.43 0.0652
MCH (rr 26e32 pg) 0.10  0.78 0.17  0.64 0.60  0.46 0.2932
MCHC (rr 330e370 g/L) 0.02  0.67 0.04  0.85 0.82  0.63 0.1308
RDW (rr 10.9e15.7%) 0.12  1.26 0.08  0.45 0.40  0.33 0.0894
PDW (rr 15.5e18.5%) 0.12  0.74 0.48  0.90 0.56  0.61 0.1675
PCT (rr 0.1e1%) 0.02  0.04 0.01  0.05 0.02  0.04 0.3395
MPV (rr 6.3e10 fL) 0.19  0.47 0.10  0.74 0.14  0.21 0.8600
Segmented cells (rr 40e80 %) 1.64  5.92 5.58  6.60 1.76  2.25 0.0726
Monocytes (rr 2e10%) 0.79  0.84 0.91  0.84 0.02  1.00 0.3157
Lymphocytes (rr 15e45%) 0.83  5.91 4.69  6.43 1.78  2.15 0.0997
*p < 0.05.
ESR Z erythrocyte sedimentation rate; MCH Z mean corpuscular hemoglobin; MCHC Z mean corpuscular hemoglobin concentration;
MCV Z mean corpuscular volume; MPV Z mean platelet volume; PCT Z plateletcrit; PDW Z platelet distribution width; RBC Z red
blood cell; rr Z reference range; WBC Z white blood cells.
Table 10 A comparison of the liver function test results between the distillation Sanyak (DDG), alcohol Sanyak (ADG), and
normal saline groups (NDG) before and after the injections.
DDG ADG NDG p
KruskaleWallis test
Total protein (rr 65e80 g/L) 0.07  0.25 0.16  0.27 0.18  0.19 0.0451*
Albumin (rr 35e53 g/L) 0.12  0.22 0.10  0.20 0.10  0.12 0.0651
A/G ratio (rr 1.1e2.5) 0.07  0.13 0.01  0.11 0.00  0.00 0.4688
T-bilirubin (rr 2.0e12 mg/L) 0.10  0.34 0.21  0.26 0.00  0.33 0.3703
AST (rr 0e40 IU/L) 0.70  5.73 0.06  4.00 3.00  4.35 0.3878
ALT (rr 0e35 IU/L) 0.80  10.69 1.30  6.11 3.40  4.27 0.1395
ALP (rr 96e254 IU/L) 1.10  8.29 1.70  3.52 2.80  5.58 0.4833
g-GTP (rr 0e73 IU/L) 1.20  9.54 3.80  7.00 2.00  3.39 0.1328
Cholesterol (rr 1.25e2.50 g/L) 7.30  18.55 3.70  24.23 5.60  5.54 0.9526
Triglyceride (rr 0.42e1.68 g/l) 20.50  85.46 91.60  206.05 22.80  33.77 0.5610
HDL-C (rr 300e650 mg/L) 0.70  4.96 2.30  4.15 1.10  2.22 0.2023
LDL-C (rr 0e1.4 g/L) 7.23  13.84 8.96  18.28 5.92  1.92 0.6464
FBS (rr 0.70e1.10 g/L) 4.30  10.36 5.80  8.54 2.00  6.61 0.8929
Creatinine (rr 6.0e12 mg/L) 0.01  0.08 0.02  0.18 0.10  0.18 0.3587
BUN (rr 80e200 mg/L) 1.87  2.48 0.92  2.93 1.78  3.06 0.7283
Mean  standard deviation.
*p < 0.05.
A/G Z albumin/globulin; ALP Z alkaline phospatase; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase;
BUN Z blood urea nitrogen; FBS Z fasting blood sugar; g-GTP Z g-glutamyltranspeptidase; HDL-C Z high-density lipoprotein-
cholesterol; LDL-C Z low-density lipoprotein-cholesterol; rr Z reference range.
50 M.-k. Ko, K.-e. HongIn the complete blood cell counts, the hematocrit level
was increased in the ADG but decreased in the DDG and in
the NSG after the injections (p Z 0.0272; Table 11). The
hematocrit is the percentage of the red blood cell volume
and is used to diagnose anemia. The change in thehematocrit levels were within normal limits, and did not
significantly affect the safety of Sanyak pharmacopuncture.
There was no statistical significance in the urinalysis
results before and after the injections. The Sanyak phar-
macopuncture is safe according to the urinalysis results.
The safety of Sanyak pharmacopuncture 515. Conclusion
The changes that occurred after the injections were
within normal limits. In addition, other severe adverse
event was not found, excluding pain after the injection
according to the extraction method. Therefore, Sanyak
pharmacopuncture is safe and may be useful in the
treatment of many diseases.
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